Janux Therapeutics (NASDAQ:JANX) PT Raised to $63.00

Janux Therapeutics (NASDAQ:JANX - Free Report) had its target price boosted by HC Wainwright from $50.00 to $63.00 in a report issued on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

JANX has been the topic of a number of other research reports. William Blair reissued an outperform rating on shares of Janux Therapeutics in a research report on Tuesday, February 27th. Wedbush raised their target price on Janux Therapeutics from $53.00 to $74.00 and gave the company an outperform rating in a report on Wednesday, May 8th. Cantor Fitzgerald reiterated an overweight rating and set a $100.00 price target on shares of Janux Therapeutics in a research note on Thursday. Jonestrading initiated coverage on shares of Janux Therapeutics in a report on Tuesday, April 16th. They set a buy rating and a $70.00 target price on the stock. Finally, BTIG Research began coverage on Janux Therapeutics in a research report on Thursday, March 21st. They set a buy rating and a $62.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Janux Therapeutics presently has a consensus rating of Buy and a consensus target price of $69.50.

Janux Therapeutics Stock Up 2.2 %

NASDAQ:JANX traded up $1.07 on Monday, reaching $49.99. The company's stock had a trading volume of 863,919 shares, compared to its average volume of 787,519. Janux Therapeutics has a 12-month low of $5.65 and a 12-month high of $65.60. The stock has a 50 day moving average price of $45.44 and a 200 day moving average price of $23.42. The firm has a market cap of $2.59 billion, a price-to-earnings ratio of -40.98 and a beta of 3.87.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Friday, March 8th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.12. Janux Therapeutics had a negative net margin of 762.92% and a negative return on equity of 13.49%. The company had revenue of $2.46 million for the quarter, compared to analysts' expectations of $0.98 million. Equities research analysts expect that Janux Therapeutics will post -1.35 EPS for the current fiscal year.

Institutional Trading of Janux Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC lifted its position in shares of Janux Therapeutics by 10,740.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company's stock worth $29,000 after buying an additional 2,685 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Janux Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 14,204 shares of the company's stock valued at $152,000 after purchasing an additional 3,602 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Janux Therapeutics by 82.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,743 shares of the company's stock worth $367,000 after purchasing an additional 4,400 shares during the period. ProShare Advisors LLC purchased a new position in Janux Therapeutics in the 1st quarter valued at $251,000. Finally, Lester Murray Antman dba SimplyRich acquired a new position in Janux Therapeutics in the 1st quarter valued at $300,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.